By Author
  By Title
  By Keywords

January 1993, Volume 43, Issue 1

Original Article


Muhammad Tayyab  ( Postgraduate Medical Institute, K.E. Medical College, Lahore. )
Allaha Ditta  ( Postgraduate Medical Institute, K.E. Medical College, Lahore. )
Mahmood Ali Malik  ( Postgraduate Medical Institute, Mayo Hospital, Lahore. )
Sardar W. Ashraf Khan  ( 1447-E, Spatan Village, Michigan State University, Michigan, USA. )
Naseer Ahmad Chaudhry  ( Postgraduate Medical Institute, K.E. Medical College, Lahore. )


Thyroid microsomal antibody (MsAb) was estimated in 48 patients with Graves disease (15 newly diagnosed, 15 on drugs for about 4 weeks and 18 euthyroid with drug treatment) and twenty age and sex matched controls. The diagnosis of Graves’ disease (GD) was based on clinical history, physical examination and thyroid function tests, viz. 1311 uptake, thyroid scintigram and serum T3, T4 and TSH levels. MSAb was positive in 93.3% of newly diagnosed as well as hyperthyroid GD patients on drugs. Eighty-three percent euthyroid GD patients and 20% normal controls also showed MSAb positivity. The titres of newly diagnosed patients were significantly raised (P <0.05) than those of euthyroid patients and controls indicating the diagnostic as well as prognostic significance of MSAb in Graves’ disease (JPMA 43: 11, 1993).


Graves’ disease is a multisystem disorder of im­munological origin. It is characterized by hypcr­thyroidism with diffuse toxic goitre, ophthalmopathy and dermopathy. The immunoglobulins directed against a receptor result in sustained stimulation of the target organ1. The disease is more prevalent in iodine rich areas (iodine content 2.0 pg/i) as compared to iodine deficient areas2. Several autoantibodies have been found in the scra of GD patients3. The detection of autoan­tibodies has diagnostic implications4. Thyroid micro­somal antibody (MSAb) in serum correlates with lym­phoid infiltration of the thyroid gland and is detected in most patients of autoimmune thyroid disease (AJTD) including, primarily, Graves’ disease and Hashimoto’s thyroiditis5. It may be beneficial to include this test in screening programme of pregnant women for postpar­turn painless thyroiditis. MSAb estimation is also useful to differentiate exophthalmos from other causes of orbital swelling6. The microsomal antigen (M-Ag) is a glycoprotcin and contains at least two antigenic determinants. Dif­ferent patients have different antibodies against these epitopes7. The M-Ag normally located at the microvillar edge of thyroid follicles may be shifted to the vascular pool because of change in thyroid epithelial polarity thus permitting direct approach of circulating MSAb to the ‘microsomal’ follicular autoantigen8. The thyroid microsomal antibody participates in follicular cell damage by mediating complement dependent antibody mediated cytoxicity9. The structure presently referred to as M-Ag is identified thyroid pcroxidase (TPO) which is a complex glycoprotein with a prosthetic group10. The correlation of MSAh and TPO antibody titres was a general phenomenon independent of the nature of underlying AITD and what was presently called as MSAb arc antibodies directed towards TPO11,12 This study was aimed to estimate the titres of MSAb in GD patients at different stages of treatment.


Forty-eight patients with Graves’ disease (29 females and 19 males aged 14 to 60 years) and twenty age and sex matched control subjects were included in the study. They were divided into four groups: group A included newly diagnosed GD patients (15), group B were hyperthyroid GD patients undergoing methamizole therapy (15), group C were patients who had been rendered euthyroid after methamizole treatment (18) and group D included 20 controls who had neither systemic disease nor endocrine disorder. All patients were selected from thyroid clinic, Mayo Hospital, Lahore. The diagnosis of Graves’ disease was made on Wayne’s clinical diagnostic index13, thyroid function tests, radioactive iodine (131J) uptake, thyroid scans, serum T4. T3 and TSH using T4 RIA, T3 RIA and TSH RIA kits (Amersham International Ltd., Amersham Buck­inghamshire, England). All sera were stored at -4°C till required. Thyroid microsomal antibody (MSAb) was estimated using the Serodia-AMC kit (Fujcribio Inc., Tokyo, Japan). The test was based on indirect agglutination/microtitration tech­nique14. Statistical analysis was done using students \\\'t\\\' test.


Thyroid microsomal antibody was positive in 93%, 93%, 83% and 20% cases in group A, B, C and D respectively (Table I).

Titrcs of MSAh in GD patients and controls are shown in Table II.

There was no difference in the mean titres between new GD patients and hyperthyroid patients on drugs; however, significant difference (P <0.05) was noted in the mean titres in newly diagnosed patients, euthyroid patients and controls.


Graves’ disease is an autoimmune thyroid disorder characterized by the presence of autoantibodies directed against the TSI-l receptors or nearby regions of thyroid cell membrances15. Circulating thyroid microsomal antibodies are frequently detected that react with the thyroid microsomal antigen16. Though not conclusive, there is evidence that these MSAb are of importance in the pathogenesis of GD17. We detected MSAb in 93.3% of newly diagnosed as well as hyperthyroid GD patients on drugs. Antibodies were present in 83.3% euthyroid GD patients also. Several other investigators have also reported MSAb positivity in GD patients varying from 76-90%18-20. The differences in antibody positivity may be due to racial and ethnic differences, methods of estimation and arbitrarily set limits between positive and negative results by various laboratories, Twenty percent controls were also an­tibody positive in our study which is similar to 10-20% reported by others5,18,21. It can he inferred that oc­casional finding of MSAb in the sera of otherwise healthy subjects is of no significance. It is, however, important to realise that accidental finding of MSAb in apparently healthy individuals may probably indicate unrecognised or incipient disease22. Significant reduction in antibody Litres were noted in group C patients when compared to group A has been reported at the end of a course of MMI therapy23. This change in the autoantibody levels was suggested to be due to the immunosuppressive action of MMI24. Accord­ing to Romaldini et al25 fall in the MSAh levels of euthyroid GD patients was due to a decreased availability of the microsomal autoantigen to the immune system. Thus it is suggested that reduction in the MSAb titres of euthyroid GD patients may be considered as an indicator of immunological remission. Since the natural history of GD is one of the remissions and relapse, overall 30% spontaneous remission is generally accepted26. Accord­ing to kandall-Taylor27, GD patients after MMI therapy showed remission rates from 30-75% depending on the duration of treatment. Individual susceptibility to MMI has been demonstrated in GD patients by the unpre­dictability of the clinical course after cessation of the drug. This effect may be due to iodine intake, racial and ethnic changes and severity of hyperthyroidism28. Thus a laboratory test is required that will guide whether immunological remission besides biochemical remission (normal serum T3 and T) has occurred or not. The assay of thyroid stimulating antibody (TSAb) had been claimed to be the test of choice but the technical difficulties militate against its clinical usefulness29. Hence, in our opinion the detection of microsomal antibodies by microtitration technique which is cheaper and easier to perform should he instituted in the diagnosis and assessment of GD patients under treatment and at follow-up.


1. Larsen, l’.R. The thyroid, in Cecil’s textbook of medicine. 19th ed. Philadelphia, Saunders, 1992 pp. 1248-71.
2. Stewart, AG. Pot- debate: drifting continents and endemic goiter in northern Pakistan. Br.MedJ., 1990:300:1507-12.
3. Ashraf, S.W.K. and Tavyab. M. Long acting thyroid stimulator in Graves’ disease. Pakistan. .1.Med. Res., 1989:28;131-34.
4. Bjoro. T., Gaardcr, P.1., Smeland, CIt. and Kornstad, L. Thyroid antibodies in blood donors; prevalence and clinical significance. Acta Endocrinol., 198.1: 105:324-29.
5. 1lawkins, BR., Cheah, P.S., Dawkins. R.L, Wbittingham, S.. Burger, H.G., Patel, Y., Mackay, L.R. and Welborn, T.A. Diagnostic significance of thyroid microsomal antibodies in randomly selected population. Lancct, 1980:2:1057-59.
6. Amino, N. Antithyroid antibodies, in Werner’s the thyroid. 5th ed. Philadelphia, Lippincot, 1986: pp. 546-59.
7. Hamada, N., Grimm, C.. Mori. H. and DeGrool, L.J. Identification of a thyroid microsomal antigen by western blot and immunoprecipitation. J.Clin. Endocrinol. Metab., 1985;61:120-28
8. Mariotti, S., Chiovato, P.. Vitti, P. etal. Recentadvancesin theunderstandingof humoral and cellular mechanisms implicated in thyroid autoimmune disorders. Clin. Immunol. Immunopath. 1989:50:S73-S84.
9. Kboury, E.L., Hammond. L., Bottazzo, G.F. and Doniach. D. Presence of the oi’gan.speciflc "microsomal" autoantigen on the surface of human thyroid cells in culture; its involvement in complement mediated cytyxicity. Clin.Exp. Im­munol., 1987;45:316-28.
10. Pinchera, A., Mariotti, S., Chiovato, L, Vitti. P., Lopez, G., Lombardi, A., Anelli, S., Bechi, R. and Carayon, P. Cellular localizationof the microsomal antigen and the thyroid peroxidase antigen. Ada Endocrinol. Suppl. (Copcnh), 1987;281:57-62.
11. Mariotti. S., Anelli. S., Ruf, J., Bechi, R.. Czarnocka. B., Lambardi, A., Carayon, P. and Pinchera, A. Comparison of serum thyroid microsomal and thyroid peroxidase auto-antibodies in thyroid diseases. J.Clin.Endocrinol. Metab., 1987:65:987-93.
12. Mariotti, S., Caturgeli, P., Piccolo, P., Barbesino, 0. and Pinchera, A. Antithyroid peroxidase autoantibodies in thyroid disease. J.Clin. Endocrinol. Metab., 1900;71:661­69.
13. Raing, A.J. I. and Capper, W.M. Bailey and Love’s short practice of surgery. 15th ed. London, Levis. 1971, P. 572.
14. Roitt, TM., Brostoff, .1. and Mole, D.K. ed. Immunology, London, Gower Medical PubI..1985, p.25.2
15. Laurent. E., Van-Sande, 3,1., Ludgate, M., Corvilian. B., Rocman’s, P., Dumont, J.E, and Moekell, J. Unlike thyrodropin, thyroid-stimulating antibodies do not activate phos­pholipase C in human thyroid slices. J.Clin.Invest., 1991;87:1634-42.
16. Belcher, M. and Bar, R.S. Autoimminity in thyroid disorders: Graves’ disease, in receptors and human disease. Baltimore, Williams and Wilkins, 1981, pp.219-35.
17. Real, G.N. and Solomon. D.H. Hashimoto’s disease and Graves’ disease, Immunological disease. Samter MAx.(ed) 3rd ed. Boston, Little Brown, 1978, vol.2 pp. 1261-77.
18. Ingbar, S.H. The thyroid gland, William’s textbook of endocrinology. 7th ed Philadel­phia, Saunders, 1985, pp.682-815.
19. Lucas-Martin. A.. Foz-Sala, M., ‘l’odd, I., Bottazzo, G.F. and Pujol-Boreell, R. Occurrence of thyrocyte HLA class II expression in a wide variety of thyroid diseases. Relationship with lymphocytic infiltration and thyroid autoantibodies. J.Clin.En­docrinol. Metab., 1988,66:367-75.
20. Volpe, R. Pathogenesis of autoimmune thyroid disease, in Werner’s the thyroid. Philadelphia, Lippincott, 1986, pp. 747-67.
21. Hamada, N., Jaeduck, N., Portmann, L., Ito, K. and DeGroot, Li. Antibodies against denatured and reduced thyroid microsomal antigen in autoimmune thyroid disease. 3. Clin. Endocrinol. Metab., 1987:64:230-38
22. Sherbaum, W.A. On the clinical importance of thyroid microsomal and thyroglobulin antibody determination. Acts Endocrinol. (Copenh), 1987;281:325.29.
23. Karlsso, F.A. and Totterman, TN. Immunomodulation by methimazote therapy in Graves’ disease: rapid changes in activation stageof circulating regulatory T cell subsets, Btellsand NKcells. Clin. Exp. Immunol., 1988:74:258-63.
24. Mashio. Y., Beniko, M., lkota. A., Mizumoto, H. and Kunita, H. ‘rrcatmcnt of hyperthyroidism with a small single daily dose of methimazole. Acta Endocrinol. (Copenh), 1988:119:139-44.
25. Romaldini, 3.1 I., Werner, M.C., Rodrigues. H.F., Teixeria. V.1,., Warner, R.S., Farah, CS. and Bromberg. N. Graves’ diseaseand Hashimoto\\\'s thyroiditis: cffectsofhighdoses ofantithyroi drugs on thyroid autoantibody levels. J.Endocrinol., Invest., 1986;9:233-38
26. codacioni, J.L., Orgiazzi, J., Blanc, P., Pugeat. M., Router, R. and Carayon, P. Lasting remiaaion in patienta treated for Gravea’ hyperthyroidism with propranolol alone; a pattern of apontaneoua evolution of the disease. J.Clin.Endocrinol. Metab., 1988;67:656- 62.
27. Kandall-Taylor,P. Arc antithyroid drugt immuno-auppreasive? Br.MedJ., 1984;288:509-10.
28. Solomon, B.L., Evaul, I.E., Burman, K.D. and Wartofsky, L. Remission rates with antithyroid drug therapy; continuing influence of iodine intake? Ann.Intern.Med., 1987;107:5 10-12.
29. Muratami, M., Koizumi, Y., Aizawa, T., Yamada, T., Takahaahi, Y., Watanabe, T. and Kamol, K. Studiea of thyroid function and immune parameters in Graves’ disease in remission J.Clin.EndoerinoL Metab., 1988;66:103-8.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: